3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Multiple Endocrine Neoplasia Type 2a
1
Lethal Congenital Contracture Syndrome 2
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
52
Paclitaxel
19
Cisplatin
14
Carboplatin
14
lenvatinib
10
Docetaxel
8
Saline Solution
7
Capecitabine
7
Pemetrexed
6
Oxaliplatin
6
Gemcitabine
6
Fluorouracil
6
Leucovorin
5
Albumin-Bound Paclitaxel
5
olaparib
4
belzutifan
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
patritumab deruxtecan
3
Glucose
3
Acetaminophen
3
liposomal doxorubicin
2
Levoleucovorin
2
Irinotecan
2
Histamine H2 Antagonists
2
Histamine Antagonists
2
Etoposide
2
Doxorubicin
2
Dexamethasone
2
Cetuximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Antibodies, Bispecific
×
90 days
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled